EIKN Stock Forecast: Eikon Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Eikon Therapeutics, Inc. is $28. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 5 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Eikon Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (65): Analysts have, on balance, been raising their forecasts.
Volatility (1): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
EIKN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on EIKN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 11 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Nov 2026 | Morgan Stanley | Maintains | Overweight | $32 → $30 |
| 16 Oct 2026 | HC Wainwright & Co. | Initiates | Buy | $23 |
| 14 Aug 2026 | Wedbush | Maintains | Underperform | $5.00 → $4.00 |
| 12 May 2026 | Wedbush | Maintains | Underperform | $7.00 → $5.00 |
| 31 Mar 2026 | Wedbush | Reiterates | Underperform | — |
| 2 Mar 2026 | B of A Securities | Initiates | Buy | — |
| 2 Mar 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 2 Mar 2026 | JP Morgan | Initiates | Overweight | — |
| 2 Mar 2026 | Mizuho | Initiates | Outperform | — |
| 2 Mar 2026 | Morgan Stanley | Initiates | Overweight | — |
| 26 Feb 2026 | Wedbush | Initiates | Underperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for EIKN.
This page is one stock. Monday covers all of them.
EIKN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
EIKN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
EIKN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 81% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −90.9%
- Return on assets
- −32.8%
- Dividend yield
- —
Higher than 15% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Eikon Therapeutics, Inc. has a market value of $256.8M and an enterprise value of $44.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$322.2M.
Free cash flow in the twelve months to 30 June 2026: −$259.2M.
Eikon Therapeutics, Inc. employs 384 people.
Data provided by Twelve Data
EIKN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at EIKN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Eikon Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about EIKN
What is the EIKN stock price forecast for 2026-2027?
The median 12-month analyst price target for Eikon Therapeutics, Inc. is $28, with estimates ranging from $4 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is EIKN stock a buy right now?
Of the 7 analysts covering Eikon Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Eikon Therapeutics, Inc. 5 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank EIKN?
As at 21 Nov 2026, Eikon Therapeutics, Inc. ranks 5 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (65 of 100).
Will EIKN stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts is $28, and Ticker Nerd's factor model ranks Eikon Therapeutics, Inc. 5 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the EIKN stock forecast for 2030?
No analyst covering Eikon Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EIKN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $32 over the next 12 months.
What does Eikon Therapeutics, Inc. do?
Eikon Therapeutics Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative medicines for serious unmet medical needs. Eikon Therapeutics Inc. concentrates primarily on oncology, advancing a pipeline of product candidates designed to target difficult-to-treat cancers and other solid tumors.
About Eikon Therapeutics, Inc.
Eikon Therapeutics Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative medicines for serious unmet medical needs. Eikon Therapeutics Inc. concentrates primarily on oncology, advancing a pipeline of product candidates designed to target difficult-to-treat cancers and other solid tumors. Its current programs include antibody-free and small-molecule therapies that act on pathways such as immune activation, DNA repair, and androgen receptor signaling. The company also uses a proprietary drug discovery platform that combines super-resolution microscopy, automation, data science, machine learning, and software engineering to study protein behavior in living cells and guide target identification. Headquartered in Millbrae, California, Eikon Therapeutics Inc. plays a role in the biopharmaceutical market by translating advanced biology and engineering into clinical-stage therapeutic development.
CEO Dr. Roger M. Perlmutter M.D., Ph.D. · 384 employees · United States · https://eikontx.com